Capstone Capital Management Ltd Takes Position in WAVE Life Sciences Ltd. $WVE

Capstone Capital Management Ltd acquired a new stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 144,029 shares of the company’s stock, valued at approximately $1,044,000. WAVE Life Sciences comprises approximately 1.0% of Capstone Capital Management Ltd’s portfolio, making the stock its 24th biggest position. Capstone Capital Management Ltd owned approximately 0.08% of WAVE Life Sciences as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Private Advisor Group LLC bought a new position in WAVE Life Sciences in the 1st quarter worth about $160,000. Y Intercept Hong Kong Ltd bought a new stake in shares of WAVE Life Sciences during the first quarter valued at approximately $1,138,000. Pictet Asset Management Holding SA boosted its holdings in shares of WAVE Life Sciences by 42.6% in the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock valued at $8,202,000 after purchasing an additional 343,226 shares during the period. James J. Burns & Company LLC boosted its holdings in shares of WAVE Life Sciences by 8.5% in the first quarter. James J. Burns & Company LLC now owns 114,800 shares of the company’s stock valued at $832,000 after purchasing an additional 8,998 shares during the period. Finally, Hsbc Holdings PLC grew its stake in WAVE Life Sciences by 52.1% in the fourth quarter. Hsbc Holdings PLC now owns 16,990 shares of the company’s stock worth $291,000 after purchasing an additional 5,823 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on WVE. Truist Financial initiated coverage on WAVE Life Sciences in a research note on Wednesday, April 29th. They set a “buy” rating and a $15.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of WAVE Life Sciences from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Monday, April 20th. Wall Street Zen raised shares of WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, New Street Research set a $13.00 target price on shares of WAVE Life Sciences in a research report on Thursday, June 11th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, WAVE Life Sciences has an average rating of “Moderate Buy” and an average target price of $26.41.

WAVE Life Sciences Price Performance

NASDAQ:WVE opened at $6.24 on Thursday. The company’s fifty day moving average price is $6.31 and its 200-day moving average price is $10.21. WAVE Life Sciences Ltd. has a 1-year low of $5.02 and a 1-year high of $21.73. The firm has a market capitalization of $1.20 billion, a P/E ratio of -5.89 and a beta of -1.29.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.21. The company had revenue of $38.25 million for the quarter, compared to analyst estimates of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. Equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.1 EPS for the current fiscal year.

WAVE Life Sciences Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.